

Data quality for evaluation

Lead Registrants Workshop, ECHA

2 February 2012

Watze de Wolf

Evaluation Unit E3



Outline

- Evaluation overview
- Dossier evaluation: compliance check
 - Feedback on data quality
- Dossier evaluation: testing proposal examination
 - Feedback on data quality
- Dossier evaluation: general recommendations
- Substance evaluation: initial recommendations
- Key messages for Registrants

Evaluation overview

MSCAs

Dossier evaluation

Substance evaluation

Check test proposals

Compliance check

Examine any information on a substance

Output, e.g.:

- accept/reject a testing proposal
- request information, because the dossier is not compliant

Dossier Evaluation: compliance check process

Evaluation type	ECHA questions	ECHA examination conclusions	Numbers and timelines
Compliance Check (CCH)	Information requirements adequately fulfilled? Adaptations adequately justified?	Article 41(3) draft decision: <ul style="list-style-type: none"> • Request further information Other outcomes: <ul style="list-style-type: none"> • Quality Observation Letter – indicates elements to be improved • No further action 	Select at least 5% of total received for each tonnage band <ul style="list-style-type: none"> • draft decision within 12 months of start CCH

Dossier Evaluation: compliance check feedback (i)

- Identity of the registered substance – describe it clearly
- Adaptation to the standard information requirements
 - must meet the conditions set out in Annex XI or in column 2 of Annexes VII – X of REACH Regulation;
 - sufficient justification for any adaptation should be provided;
- Robust study summaries: sufficient level of detail required to allow an independent assessment of information provided
- Classification and labelling: in line with the hazards identified or harmonized classification and labelling

Dossier Evaluation: compliance check feedback (ii)

- Check consistency
 - Between CSR and IUCLID file
 - Between different parts of the CSR
- Always provide justifications for
 - Omission or modification of a standard CSR element (see REACH Annex I)
 - Deviations from guidance documents
- Qualitative assessment and justifications are not just statements
 - Detailed reasoning and supporting data are required
- Ensure transparency
 - Give details on model assumptions, versions, input parameters
- Use of Chesar and QSAR toolbox is recommended

Dossier Evaluation: testing proposal evaluation process

Evaluation type	ECHA questions	ECHA examination conclusions	Numbers and timelines
Testing Proposal Examination (TPE)	<p>Proposed test adequate and justified?</p> <p>Unnecessary animal testing avoided?</p>	<p>Article 40(3) draft decision:</p> <ul style="list-style-type: none"> • Accept testing • Reject testing • Change test conditions • Request additional testing 	<p>All testing proposals</p> <ul style="list-style-type: none"> • non phase-in: draft decision in 6 months • phase-in submitted by 1 Dec 2010: draft decision by 1 Dec 2012

Dossier Evaluation: testing proposal evaluation feedback (i)

- Submit proposals for tests required under Annex IX and X before undertaking them
 - Performing testing without an approving ECHA decision may lead to enforcement actions
- Provide adequate Substance identity information
 - Registered substance
 - Test material
- Check consistency between IUCLID file and CSR
 - Make sure the testing proposal is present in IUCLID
 - Do NOT propose testing only in CSR
- Be clear that you are proposing a new test
 - choose correct study type in IUCLID: “Experimental study planned”

Dossier Evaluation: testing proposal evaluation feedback (ii)

- In case of using category/read across approach:
 - Provide justification on why you think this is appropriate
 - Consider legal text Annex XI 1.5 of REACH
 - Strengthen your rationale for read-across
 - Not “wishful” thinking but “more information is better”
 - Value generated by prediction must be adequate for the purpose of risk assessment and/or classification and labelling
 - Information must be equivalent or better quality
- IUCLID
 - Include robust study summaries on the read across substance (including read-across test material data) in your IUCLID file
 - Ensure the category justification is clearly presented in IUCLID
 - Do NOT propose category approach only in CSR

Dossier Evaluation: recommendations (i)

- Continuous development of new test methods
- Follow the latest developments on current status of methods and their applicability
 - *in vitro* methods: Tracking System for Alternative test methods review, Validation and Approval in the Context of EU Regulation on Chemicals (TSAR);
 - <http://tsar.jrc.ec.europa.eu>
- Extended One-Generation Reproductive Toxicity Test (OECD TG 443)
 - ECHA considers the test guideline can be used
 - The modular nature of the guideline requires further specification of the study design to meet information requirements for Annex IX and X, 8.7.3 of the REACH Regulation
 - This is still under discussion between the Member States and European Commission
- Transgenic Rodent Somatic and Germ Cell Assays (OECD TG 488; Annex IX, 8.4 of the REACH Regulation)
- Chronic Toxicity to Higher Plants (ISO 22030; Annex X 9.4.6 of the REACH Regulation)

Dossier Evaluation: recommendations (ii)

- Chemical safety assessment
 - *"To assess and document that the risks arising from the substance...[]...are adequately controlled"* (Annex I Section 0.1)
- Hazard assessment
 - Follow advice of ECHA Guidance on use of assessment factors (AF) and derivation of no-effect levels (DNELs)
 - Justify and document your choice and any deviations in approach
- PBT assessment
 - Take into account and address all available information on your substance (e.g. substance is on candidate list of SVHC)
 - Minimisation of emissions for PBT substances needs to be demonstrated
- Exposure assessment, risk assessment and risk characterisation
 - Adapt generic exposure scenarios to the identified uses
 - Describe sufficiently and concretely operational conditions and risk management measures
 - Demonstrate safe use of your substance

<http://echa.europa.eu>

Substance evaluation: Recommendations

- CoRAP (to be published end February 2012)
 - Is your substance **on the CoRAP**?
 - Get prepared within your consortium!
- Substance evaluation draft decisions will be prepared **within one year**
 - Could result in further requests for information. Such as:
 - Testing requirements that go beyond the REACH standard information requirements
 - Exposure related information
- Be prepared to handle the incoming draft decisions
- Organise your commenting (same timelines as under Dossier Evaluation)

Key Messages for Registrants

- **Do not consider your registration dossier as a final product once submitted**
 - Take a pro-active approach and update your dossiers when new information on hazards or uses becomes available
 - Take into account the recommendations in the yearly Article 54 report
 - Do not await the outcome of potential compliance checks - improve the quality of the dossiers through updates on your own initiative
 - Make use of the informal communication offered by ECHA
 - Further compliance checks will be conducted and reporting on the results will improve the quality of the dossiers

Thank You!

Watze de Wolf

watze.dewolf@echa.europa.eu

